September looms as a risk month for stocks, Yardeni says
CAMBRIDGE, U.K.—Travis Thompson, the Chief Accounting Officer of Bicycle Therapeutics PLC (NASDAQ:BCYC), a $1.03 billion market cap biotech company, has recently reported a series of transactions involving the company's ordinary shares. The stock, which has declined 26% over the past six months, is currently trading at $14.88. According to a filing with the Securities and Exchange Commission, Thompson executed multiple sales on January 2, 3, and 6, 2025, totaling $67,292.
On January 2, Thompson sold 1,750 shares at a weighted average price of $14.09, generating proceeds of $24,667. The following day, he sold an additional 159 shares at an average price of $14.75, adding $2,335 to the total. On January 6, a larger transaction occurred with the sale of 2,686 shares at $15 per share, totaling $40,290. These sales were conducted to cover statutory tax withholding obligations related to the vesting and settlement of restricted stock units, as mandated by the award agreement.
Following these transactions, Thompson holds 32,146 ordinary shares of Bicycle Therapeutics.
In other recent news, the biopharmaceutical firm Bicycle Therapeutics has experienced notable developments. B.Riley significantly adjusted the company's price target from $28.00 to $17.00 while maintaining a Neutral rating, following the release of clinical data for zelenectide pevedotin that did not meet expectations. H.C. Wainwright also adjusted its price target for Bicycle Therapeutics, reducing it to $33.00 from the previous $55.00, but maintained its Buy rating.
Morgan Stanley (NYSE:MS), on the other hand, kept its Equalweight rating on Bicycle Therapeutics with a steady price target of $30.00, emphasizing the clarity provided on the Phase 2/3 Duravelo-2 trial timing as a positive development. Meanwhile, Needham retained its Buy rating and a $38.00 stock price target for Bicycle Therapeutics, anticipating promising early results for the monotherapy in patients with triple-negative breast cancer. Leerink Partners raised the company's price target to $32.00, maintaining an Outperform rating, following the company's third-quarter financial results and pipeline progress.
These are some of the recent developments surrounding Bicycle Therapeutics, highlighting the varying perspectives of different analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.